Table 5.
Univariate and multivariate analyses of risk factors for OS of FP and RP.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p-value | HR | 95%CI | p-value | |
| Age | ||||||
| ≥65 vs <65 | 0.59 | 0.31-1.14 | 0.114 | |||
| Sex | ||||||
| female vs male | 0.91 | 0.41-2.01 | 0.811 | |||
| ECOG PS | ||||||
| 0 vs 1 vs 2 | 2.42 | 1.41-4.17 | 0.001 | 2.80 | 1.35-5.80 | 0.006 |
| Tumor location | ||||||
| Left vs right | 1.02 | 0.47-2.25 | 0.956 | |||
| Site of primary tumor | ||||||
| Rectum vs colon | 1.09 | 0.58-2.06 | 0.779 | |||
| Liver metastasis | ||||||
| yes vs no | 2.35 | 1.16-4.77 | 0.018 | 1.48 | 0.62-3.52 | 0.374 |
| Lung metastases | ||||||
| yes vs no | 0.69 | 0.34-1.38 | 0.293 | |||
| Peritoneal metastases | ||||||
| yes vs no | 0.95 | 0.45-2.02 | 0.901 | |||
| Number of distant metastatic sites | ||||||
| ≥3 vs <3 | 0.89 | 0.46-1.73 | 0.727 | |||
| KRAS or NRAS mutation | ||||||
| yes vs no | 1.91 | 0.98-3.73 | 0.059 | 1.59 | 0.73-3.46 | 0.244 |
| BRAF mutation | ||||||
| yes vs no | 0.84 | 0.11-6.29 | 0.863 | |||
| Prior antitumor treatment | ||||||
| surgery vs chemotherapy or radiation therapy | 0.40 | 0.20-0.82 | 0.012 | 0.58 | 0.25-1.32 | 0.19 |
| Targeted drugs | ||||||
| fruquintinib vs regorafenib | 1.89 | 1.00-3.56 | 0.050 | 2.53 | 1.21-5.27 | 0.014 |
| Previous anti-VEGF treatment | ||||||
| yes vs no | 2.39 | 0.90-6.33 | 0.080 | 1.06 | 0.33-3.35 | 0.928 |
| Previous anti-EGFR treatment | ||||||
| yes vs no | 1.12 | 0.56-2.24 | 0.741 | |||
ECOG PS, Eastern Cooperative Oncology Group performance status; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.
The bold value in the univariate analysis represents p<0.1 and is included in the multivariate analysis; The bold values in multivariate analysis represent p<0.05, and the difference is statistically significant.